The analysis of dynamics of changes in the availability indexes of beta-blockers in Ukraine
Keywords:beta-blockers, cardiovascular diseases, availability of drugs, coefficient of adequacy of solvency
Aim. To study the dynamics of changes in the availability indexes of beta-blockers within 2013-2016.
Materials and methods. In the study the data of the legislative normative base, “Morion” information retrieval system for 2012-2016 and special literature were used. The coefficients of adequacy of solvency (Са.s.) and the availability indexes (A) were calculated. The historical, logical, graphical, mathematical and statistical research methods were used.
Results. It has been found that in the second year (2013) of implementation of the Pilot Project concerning the state price control on drugs used in the treatment of hypertension the increase of the availability is characteristic for all names of beta-blockers. In 2014-2015 there was a negative tendency to the drug availability decrease, and in 2016 on the contrary the drug availability increased. Thus, according to the data of 2016 the availability indexes of beta-blockers did not reach the “pre-crisis” values of 2013. By the average value of the availability indexes the imported drugs became more accessible than drugs of the domestic production.
Conclusions. The impact of implementation of the Pilot Project (2012-2014) and the financial and economic crisis (2015-2016) on the availability indexes of beta-blockers determines the need for further research in this area and emphasize the socio-economic relevance of introduction of effective mechanisms of reimbursement of drug consumption.
Rozenko, P. (2017). Uriadova prohrama “Dostupni liky” vzhe startuvala u vsikh oblastiakh. Uriadovyi portal. Retrieved from: http://www.kmu.gov.ua/control/uk/publish/article?art_id=249930194&cat_id=244276429
Postanova Kabinetu Ministriv Ukrainy vid 17.03.2017 No. 152 “Pro zabezpechennia dostupnosti likarskykh zasobiv”. Retrieved from: http://zakon2.rada.gov.ua/laws/show/152-2017-%D0%BF.
Baihush, Yu. V., Slobodianiuk, M. M. (2016). Sotsialna farmatsiia v okhoroni zdorov’ia, 2 (1), 13–21. doi: 10.24959/sphhcj.16.29.
Derzhavne rehuliuvannia tsin ta vidshkoduvannia likiv: takoho shche ne bulo (onovleno). (2016). Shchotyzhnevnyk “Apteka”, 45. Retrieved from: http://apteka.ua/article/391705.
Kotvitska, A. A., Korobova, Ye. S. (2016). Sotsialna farmatsiia v okhoroni zdorov’ia, 2 (4), 24– 31. doi: 10.24959/sphhcj.16.57.
Mishchenko, O. Ya., Adonkina, V. Yu. (2015). Ratsional’na farmakoterapiia, 1 (34), 27–31. Retrieved from: http://health-ua.com/stati/cardiology/antigipertenzivnyie-preparatyi-na-farmatsevticheskom-ryinke-ukrainyi-analiz-ekonomicheskoy-dostupnosti-i-potrebleniya.html.
Mnushko, Z. M., Timaniuk, I.V. (2007). Visnyk farmatsii, 1 (49), 52–57.
Nemchenko, A. S., Zharkova, S. O., Podhaina, M. V. (2012). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 4 (24), 60-64.
Iakovlieva, L. V., Mishchenko O. Ya, Adonkina V. Yu. (2015). Sotsialna farmatsiia v okhoroni zdorov’ia, 1 (1), 18–24. doi: 10.24959/sphhcj.15.3.
Jonsson B., Hansson, L. (2003). Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost–effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J. Intern. Med., 253 (4), 472–480. doi: 10.1046/j.1365-2796.2003.01135.x.
Salvetti, A., Ghiadoni, L. (2004). Guidelines for antihypertensive treatment: an update after the ALLHAT Study. Journal of the American Society of Nephrology,15 (l), 51S–54. doi: 10.1097/01.asn.0000093242.48333.3b.
Mnushko, Z. M., Trufan, S. B. (2002). Provizor, 2. Retrieved from: http://www.provisor.com.ua/archive/2002/N21/art_18.php.
Nemchenko, A. S., Halii, L. V. (2003). Monitorynh tsin na osnovni likarski zasoby. Kharkiv: NAPh, 24.
Nemchenko, A. S., Kosiachenko, K. L., Kubarieva, I. V. et al. (2008). Metodychni rekomendatsii z provedennia derzhavnoi ekspertyzy ta reiestratsii tsin na osnovni likarski zasoby. Kharkiv: NAPh, 22.
Samborskyi, O. S. (2017). Sotsialna farmatsiia v okhoroni zdorov’ia, 3 (1), 30–40. doi: 10.24959/sphhcj.17.72.
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).